LAMA4 (laminin alpha 4) is a subunit of laminins, heterotrimeric glycoproteins essential for basement membrane formation and cell adhesion. The LAMA4 antibody specifically binds to this chain, enabling researchers to study its roles in:
AML Microenvironment: Lama4⁻/⁻ MSCs upregulate inflammatory cytokines (e.g., IL-6, TNF-α) and enhance mitochondrial transfer to leukemic cells, reducing reactive oxygen species (ROS) and promoting chemoresistance .
Cancer Metastasis: In HCC, LAMA4 localizes to tumor vasculature basement membranes, facilitating angiogenesis and invasive growth .
Cellular Motility: LAMA4 inhibition disrupts actin cytoskeleton dynamics by altering Rho GTPase-activating proteins (e.g., ARHGAP11A/B) and Parvin A expression, impairing directed migration .
Diagnostic Potential: Elevated LAMA4 in HCC tissues vs. healthy liver (0.37 ± 0.25 vs. 0.18 ± 0.12 mRNA levels; P < 0.01) .
Therapeutic Targeting: Blocking LAMA4 in MSCs sensitizes AML cells to cytarabine by restoring ROS levels .
Species Specificity: Most studies use murine models; human clinical validation remains limited .
Dual Roles: LAMA4 exhibits context-dependent pro- or anti-tumor effects, necessitating tissue-specific investigations.
Technical Challenges: Antibody customization (e.g., conjugation) requires optimization for novel applications .